CYTODYN INC (CYDY)
CYDY moved a median of -0.07% 30 minutes after news, and -0.67% by the close. How CYDY actually reacts to news — the realized, point-in-time move the market made, measured across 191 labeled events over the last three years with zero look-ahead.
CYDY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 188 |
| 30-min | -0.07% | 45% | 191 |
| 60-min | -0.54% | 39% | 191 |
| to close | -0.67% | 43% | 191 |
| Middle 50% of CYDY reactions | -2.48% to +2.42% |
|---|---|
| Median reaction (30-min) | -0.07% |
| Measured reactions | 191 |
Half of all CYTODYN INC news events land between -2.48% and +2.42% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CYDY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CYDY's baseline. Nothing else.
Recent CYDY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| CytoDyn to Host Investor Webcast | Press release | GlobeNewswire | -0.30% | +2.69% | |
| Form 10-Q CytoDyn Inc. For: Aug 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.01% | +1.01% | |
| CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026 | Press release | GlobeNewswire | +0.90% | +0.65% | |
| Form EFFECT CytoDyn Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.90% | +0.65% | |
| Form EFFECT CytoDyn Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.50% | +0.00% | |
| Form DEF 14A CytoDyn Inc. For: Sep 28 | SEC filing · Form DEF | SEC EDGAR | +4.46% | -4.08% | |
| Form POS AM CytoDyn Inc. | SEC filing · Form POS | SEC EDGAR | -1.57% | +0.06% | |
| Form S-3 CytoDyn Inc. | SEC filing · Form S-3 | SEC EDGAR | -1.57% | +0.06% | |
| CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th | Press release | GlobeNewswire | +0.02% | -8.75% | |
| CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab | Press release | GlobeNewswire | +3.51% | -2.33% | |
| Form 10-K CytoDyn Inc. For: May 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +5.20% | |
| CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease | Press release | GlobeNewswire | -1.73% | +0.03% | |
| Form EFFECT CytoDyn Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.20% | -3.14% | |
| CytoDyn to Present at the LD Micro Invitational XVI | Press release | GlobeNewswire | -3.62% | -3.82% | |
| Form D CytoDyn Inc. | SEC filing · Form D | SEC EDGAR | +3.65% | -0.62% | |
| Form 8-K CytoDyn Inc. For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +2.95% | +0.62% | |
| CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer | Press release | GlobeNewswire | +4.88% | +8.30% | |
| CytoDyn to Host Investor Webcast | Press release | GlobeNewswire | -1.74% | -12.98% | |
| CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 | Press release | GlobeNewswire | -1.23% | -8.73% | |
| Form S-1 CytoDyn Inc. | SEC filing · Form S-1 | SEC EDGAR | -1.74% | -12.98% | |
| CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study | Press release | GlobeNewswire | -1.23% | -8.73% | |
| CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 | Press release | GlobeNewswire | -2.63% | -5.79% | |
| CytoDyn to Present at the AACR Annual Meeting 2026 | Press release | GlobeNewswire | +1.98% | -0.42% | |
| Form 10-Q CytoDyn Inc. For: Feb 28 | SEC filing · Form 10-Q | SEC EDGAR | -0.48% | +3.95% | |
| CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer | Press release | GlobeNewswire | +1.45% | -5.80% | |
| Form 8-K CytoDyn Inc. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +1.34% | +0.65% | |
| CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab | Press release | GlobeNewswire | +0.88% | -1.83% | |
| Form 8-K CytoDyn Inc. For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | +0.88% | -1.83% | |
| CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference | Press release | GlobeNewswire | -4.33% | -6.44% | |
| CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer | Press release | GlobeNewswire | -0.92% | -5.03% | |
| Form 10-Q CytoDyn Inc. For: Nov 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -3.54% | |
| Form EFFECT CytoDyn Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.89% | -0.86% | |
| December 2025 Letter to Shareholders | Press release | GlobeNewswire | -2.24% | +1.56% | |
| Form POS AM CytoDyn Inc. | SEC filing · Form POS | SEC EDGAR | +0.82% | +2.23% | |
| CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium | Press release | GlobeNewswire | +2.50% | +4.54% | |
| Form EFFECT CytoDyn Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.88% | -3.51% | |
| Form 8-K CytoDyn Inc. For: Nov 23 | SEC filing · Form 8-K | SEC EDGAR | -3.32% | -3.79% | |
| CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium | Press release | GlobeNewswire | +2.40% | +9.62% | |
| Form 8-K CytoDyn Inc. For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | +2.40% | +9.62% | |
| Form S-3 CytoDyn Inc. | SEC filing · Form S-3 | SEC EDGAR | +4.13% | +2.08% | |
| CytoDyn Secures $30 Million Commitment from Yorkville Advisors | Press release | GlobeNewswire | -3.89% | +0.04% | |
| Form 8-K CytoDyn Inc. For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | -3.89% | +0.04% | |
| Form DEFA14A CytoDyn Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.18% | -6.59% | |
| Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights | Press release | Business Wire | +0.00% | +0.00% | |
| Form 10-Q CytoDyn Inc. For: Aug 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +2.97% | |
| CytoDyn to Present at the LD Micro Main Event XIX Investor Conference | Press release | GlobeNewswire | +2.99% | +0.20% | |
| Form DEFA14A CytoDyn Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +3.56% | +3.87% | |
| September 2025 Letter to Shareholders | Press release | GlobeNewswire | -1.92% | +0.00% | |
| Form DEF 14A CytoDyn Inc. For: Nov 21 | SEC filing · Form DEF | SEC EDGAR | -1.92% | +0.00% | |
| CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity | Press release | GlobeNewswire | +1.81% | +2.41% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CYDY section they belong to.
Where else CYDY is measured.
CYDY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Arbutus Biopharma Corporation (ABUS) | 191 | +0.11% | 52% |
| BeiGene, Ltd. - American Depositary Shares (BGNE) | 191 | +0.11% | 52% |
| BAVARIAN NORDIC R/I S/ADR (BVNRY) | 190 | 0.00% | 29% |
| U S STEM CELL INC (USRM) | 190 | 0.00% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CYTODYN INC's median reaction calculated?
Every labeled CYDY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 191 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of CYDY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CYDY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.